| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 3462 | 2019 |
| Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open … V Subbiah, J Wolf, B Konda, H Kang, A Spira, J Weiss, M Takeda, Y Ohe, ... The Lancet Oncology 23 (10), 1261-1273, 2022 | 441 | 2022 |
| Immune dysregulation in cancer patients developing immune-related adverse events S Khan, SA Khan, X Luo, FJ Fattah, J Saltarski, Y Gloria-McCutchen, R Lu, ... British journal of cancer 120 (1), 63-68, 2019 | 197 | 2019 |
| Head and neck oncology during the COVID-19 pandemic: reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks AT Day, DJ Sher, RC Lee, JM Truelson, LL Myers, BD Sumer, L Stankova, ... Oral oncology 105, 104684, 2020 | 171 | 2020 |
| Clinical practice in PET/CT for the management of head and neck squamous cell cancer R Goel, W Moore, B Sumer, S Khan, D Sher, RM Subramaniam American Journal of Roentgenology 209 (2), 289-303, 2017 | 165 | 2017 |
| Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options SA Khan, SL Pruitt, L Xuan, DE Gerber JAMA oncology 2 (11), 1507-1508, 2016 | 163 | 2016 |
| ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016 C Dittrich, M Kosty, S Jezdic, D Pyle, R Berardi, J Bergh, N El-Saghir, ... ESMO open 1 (5), e000097, 2016 | 154 | 2016 |
| The relationship of stock prices and macroeconomic variables revisited: Evidence from Karachi stock exchange M Akbar, SA Khan, F Khan African Journal of Business Management 6 (4), 1315-1322, 2012 | 126 | 2012 |
| Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions P Vanden Borre, AB Schrock, PM Anderson, JC Morris III, AM Heilmann, ... The oncologist 22 (3), 255-263, 2017 | 89 | 2017 |
| Effect of simulation-based training on surgical proficiency and patient outcomes: a randomised controlled clinical and educational trial A Aydın, K Ahmed, T Abe, N Raison, M Van Hemelrijck, H Garmo, ... European urology 81 (4), 385-393, 2022 | 80 | 2022 |
| A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511) TK Owonikoko, SE Dahlberg, SA Khan, DE Gerber, J Dowell, RA Moss, ... Lung Cancer 89 (1), 66-70, 2015 | 72 | 2015 |
| Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma AM Heilmann, V Subbiah, K Wang, JX Sun, JA Elvin, J Chmielecki, ... Oncology 90 (6), 339-346, 2016 | 67 | 2016 |
| Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial EJ Sherman, J Harris, KC Bible, P Xia, RA Ghossein, CH Chung, N Riaz, ... The Lancet Oncology 24 (2), 175-186, 2023 | 39 | 2023 |
| Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors M Ahmed, MS Von Itzstein, T Sheffield, S Khan, F Fattah, JY Park, V Popat, ... Journal for ImmunoTherapy of Cancer 9 (6), e002349, 2021 | 39 | 2021 |
| Unique patterns of distant metastases in HPV-positive head and neck cancer R Sacks, JY Law, H Zhu, MS Beg, DE Gerber, BD Sumer, LL Myers, ... Oncology 98 (3), 179-185, 2020 | 37 | 2020 |
| Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers GW Jean, RM Mani, A Jaffry, SA Khan JAMA oncology 2 (4), 529-534, 2016 | 34 | 2016 |
| Empirical investigation of debt-maturity structure: Evidence from Pakistan A Shah, SA Khan The Pakistan Development Review, 565-578, 2009 | 34 | 2009 |
| Exploring perceptions of decision-makers and specialists in defensive machine learning cybersecurity applications: The need for a standardised approach O Alshaikh, S Parkinson, S Khan Computers & Security 139, 103694, 2024 | 31 | 2024 |
| Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling SA Khan, B Ci, Y Xie, DE Gerber, MS Beg, SI Sherman, ME Cabanillas, ... Head & neck 41 (6), 1928-1934, 2019 | 31 | 2019 |
| Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non–Squamous Non–Small Cell Lung Cancer R Govindan, M Lind, A Insa, SA Khan, D Uskov, A Tafreshi, S Guclu, J Bar, ... Clinical Lung Cancer 23 (3), 214-225, 2022 | 28 | 2022 |
